Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease

Receptor tyrosine kinases (RTKs) have provided molecular targets for the development of novel, prognosis-improving agents in many cancers; however, resistances to these therapies occur. On the cellular level, one resistance mechanism is attributed to functional RTK redundancies and compensatory cross-signaling, leading to perception of RTKs as signaling and target networks. To provide a basis for better exploitation of this network in Ewing sarcoma, we generated comprehensive qPCR gene expression profiles of RTKs in Ewing sarcoma cell lines and 21 untreated primary tumors.

Source: Molecular Oncology - December 20, 2015 Category: Cancer & Oncology Authors: Jenny Potratz, Amelie Tillmanns, Philipp Berning, Eberhard Korsching, Christiane Schaefer, Birgit Lechtape, Carolin Schleithoff, Rebekka Unland, Karl-Ludwig Schäfer, Carsten Müller-Tidow, Heribert Jürgens, Uta Dirksen Source Type: research